Citadel Advisors LLC 13D and 13G filings for Acrivon Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Citadel Advisors LLC | 1,649,664 7.400% |
15,515 (+0.95%) |
Filing |
| 2023-02-14 08:02 am Sale |
2022-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Citadel Advisors LLC | 1,634,149 7.800% |
-488 (-0.03%) |
Filing |
| 2022-11-21 4:01 pm Purchase |
2022-11-09 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Citadel Advisors LLC | 1,634,637 7.800% |
1,634,637 (New Position) |
Filing |